Trials / Completed
CompletedNCT01911637
Safety Study of Single Oral Doses of VBY-036 in Healthy Volunteers (VBY036P1A)
A Double-Blind, Randomized, Placebo-Controlled, Sequential, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-036 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Virobay Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
VBY-036 may treat or prevent nerve pain. This study aims to find the highest safe and tolerable single dose of VBY-036 in healthy volunteers. Volunteers are randomly selected to receive one dose of either a placebo or VBY-036 (10, 30, 100, 300, 600 or 900 mg).
Detailed description
Detailed description is noted in Brief Summary.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VBY-036 | Study drug VBY-036 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2013-07-30
- Last updated
- 2013-12-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01911637. Inclusion in this directory is not an endorsement.